Chemotherapy for Brain Metastases: Breast, Gynecologic and Non-Melanoma Skin Malignancies

  • Gaurav D. Shah
  • Lauren E. Abrey
Part of the Cancer Treatment and Research book series (CTAR, volume 136)


Greater than one-half of all intracranial tumors in adults represent metastases from disseminated systemic malignancies. Abundant class I evidence has been accumulated for the past two decades that demonstrates improved survival and quality of life with surgical resection or SRS for appropriate patients. In some tumor types, WBRT can effectively treat, prevent and/or delay recurrences and improve survival as well. However, several factors may preclude either surgery or radiation therapy (e.g., number of metastases, co-existing medical or neurological conditions) and in such patients the mainstay of treatment is chemotherapy or other biologic targeted therapy.


Brain Metastasis Endometrial Cancer Clin Oncol Epithelial Ovarian Cancer Germ Cell Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006;107(4):696–704.CrossRefPubMedGoogle Scholar
  2. 2.
    Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97(12):2972–7.CrossRefPubMedGoogle Scholar
  3. 3.
    van den Bent MJ. The role of chemotherapy in brain metastases. Eur J Cancer 2003;39(15):2114–20.CrossRefPubMedGoogle Scholar
  4. 4.
    Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995;13(11):2688–99.PubMedGoogle Scholar
  5. 5.
    Lluch A, Ojeda B, Colomer R, et al. Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy. Cancer 2000;89(11):2169–75.CrossRefPubMedGoogle Scholar
  6. 6.
    Bria E, Giannarelli D, Felici A, et al. Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma. Cancer 2005;103(4):672–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719–26.CrossRefPubMedGoogle Scholar
  8. 8.
    Baselga J, Carbonell X, Castaneda-Soto NJ, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005;23(10):2162–71.CrossRefPubMedGoogle Scholar
  9. 9.
    Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004;22(9):1605–13.CrossRefPubMedGoogle Scholar
  10. 10.
    Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986;58(4):832–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992;69(4): 972–80.CrossRefPubMedGoogle Scholar
  12. 12.
    Cocconi G, Lottici R, Bisagni G, et al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer investigation 1990;8(3–4):327–34.CrossRefPubMedGoogle Scholar
  13. 13.
    Zulkowski K, Kath R, Semrau R, Merkle K, Hoffken K. Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine. Journal of cancer research and clinical oncology 2002;128(2):111–3.CrossRefPubMedGoogle Scholar
  14. 14.
    Wang ML, Yung WK, Royce ME, Schomer DF, Theriault RL. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol 2001;24(4):421–4.CrossRefPubMedGoogle Scholar
  15. 15.
    Siegelmann-Danieli N, Stein M, Bar-Ziv J. Complete response of brain metastases originating in breast cancer to capecitabine therapy. Isr Med Assoc J 2003;5(11):833–4.PubMedGoogle Scholar
  16. 16.
    Abrey LE, Olson JD, Raizer JJ, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. Journal of neuro-oncology 2001;53(3):259–65.CrossRefPubMedGoogle Scholar
  17. 17.
    Christodoulou C, Bafaloukos D, Kosmidis P, et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 2001;12(2):249–54.CrossRefPubMedGoogle Scholar
  18. 18.
    Lassman AB, Abrey LE, Shah GD, et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. Journal of neuro-oncology 2006;78(3):255–60.CrossRefPubMedGoogle Scholar
  19. 19.
    Lin YC, Liu HE, Wang CH, et al. Clinical benefit and response in patients with gastric cancer to weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV). Anticancer research 1999;19(6C):5615–20.PubMedGoogle Scholar
  20. 20.
    Burris HA, 3rd, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005;23(23):5305–13.CrossRefPubMedGoogle Scholar
  21. 21.
    Lin N, Carey L, Liu M, et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. Presented at the American Society of Clinical Oncology meeting (abstract #503). Journal of Clinical Oncology 2006;24(18S).CrossRefGoogle Scholar
  22. 22.
    Geyer C, Cameron D, Lindquist D, et al. A phase III, randomized open-label, Internationsl study comparing lapatinib and capecitabine versus capecitabine in women with refractory advanced or metastatic breast cancer (abstract). Data presented at the annual meeting of the American Society of Clinical Oncology, 2006. 2006.Google Scholar
  23. 23.
    Pectasides D, Pectasides M, Economopoulos T. Brain metastases from epithelial ovarian cancer: a review of the literature. The oncologist 2006;11(3):252–60.CrossRefPubMedGoogle Scholar
  24. 24.
    McMeekin DS, Kamelle SA, Vasilev SA, et al. Ovarian cancer metastatic to the brain: what is the optimal management? Journal of surgical oncology 2001;78(3):194–200; discussion -1.CrossRefPubMedGoogle Scholar
  25. 25.
    Vlasveld LT, Beynen JH, Boogerd W, Ten Bokkel Huinink WW, Rodenhuis S. Complete remission of brain metastases of ovarian cancer following high-dose carboplatin: a case report and pharmacokinetic study. Cancer chemotherapy and pharmacology 1990;25(5):382–3.CrossRefPubMedGoogle Scholar
  26. 26.
    Cooper KG, Kitchener HC, Parkin DE. Cerebral metastases from epithelial ovarian carcinoma treated with carboplatin. Gynecologic oncology 1994;55(2):318–23.CrossRefPubMedGoogle Scholar
  27. 27.
    Watanabe A, Shimada M, Kigawa J, et al. The benefit of chemotherapy in a patient with multiple brain metastases and meningitis carcinomatosa from ovarian cancer. International journal of clinical oncology/Japan Society of Clinical Oncology 2005;10(1):69–71.CrossRefPubMedGoogle Scholar
  28. 28.
    Melichar B, Urminska H, Kohlova T, Nova M, Cesak T. Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature. Gynecologic oncology 2004;94(2):267–76.CrossRefPubMedGoogle Scholar
  29. 29.
    Hidaka T, Nakamura T, Shima T, Sumiya S, Saito S. Cerebral metastasis from a primary adenocarcinoma of the fallopian tube. Gynecologic oncology 2004;95(1):260–3.CrossRefPubMedGoogle Scholar
  30. 30.
    Lu KH, Gershenson DM. Update on the management of ovarian germ cell tumors. The Journal of reproductive medicine 2005;50(6):417–25.PubMedGoogle Scholar
  31. 31.
    Brewer M, Gershenson DM, Herzog CE, Mitchell MF, Silva EG, Wharton JT. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 1999;17(9):2670–75.PubMedGoogle Scholar
  32. 32.
    Adcock LL, Oakley GJ. A pure brain metastasis of choriocarcinoma from a mixed germ cell tumor of the ovary. Gynecologic oncology 1997;64(2):252–5.CrossRefPubMedGoogle Scholar
  33. 33.
    Rustin GJ, Newlands ES, Begent RH, Dent J, Bagshawe KD. Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. J Clin Oncol 1989;7(7):900–3.PubMedGoogle Scholar
  34. 34.
    Athanassiou A, Begent RH, Newlands ES, Parker D, Rustin GJ, Bagshawe KD. Central nervous system metastases of choriocarcinoma. 23 years’ experience at Charing Cross Hospital. Cancer 1983;52(9):1728–35.CrossRefPubMedGoogle Scholar
  35. 35.
    Evans AC, Jr., Soper JT, Clarke-Pearson DL, Berchuck A, Rodriguez GC, Hammond CB. Gestational trophoblastic disease metastatic to the central nervous system. Gynecologic oncology 1995;59(2):226–30.CrossRefPubMedGoogle Scholar
  36. 36.
    Lee WJ, Chen CH, Chow SN. Brain metastases from early stage endometrial carcinoma 8 years after primary treatment: case report and review of the literature. Acta obstetricia et gynecologica Scandinavica 2006;85(7):890–1.CrossRefPubMedGoogle Scholar
  37. 37.
    Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004;22(11):2159–66.CrossRefPubMedGoogle Scholar
  38. 38.
    Amita M, Sudeep G, Rekha W, Yogesh K, Hemant T. Brain metastasis from cervical carcinoma–a case report. MedGenMed 2005;7(1):26.PubMedGoogle Scholar
  39. 39.
    Gaussmann AB, Imhoff D, Lambrecht E, Menzel C, Mose S. Spontaneous remission of metastases of cancer of the uterine cervix. Onkologie 2006;29(4):159–61.CrossRefPubMedGoogle Scholar
  40. 40.
    Nagar YS, Shah N, Rawat S, Kataria T. Intracranial metastases from adenocarcinoma of cervix: a case report. Int J Gynecol Cancer 2005;15(3):561–3.CrossRefPubMedGoogle Scholar
  41. 41.
    Salvati M, Caroli E, Paone C, et al. Brain metastasis from cutaneous squamous cell carcinoma of the dorsum. Case report. Journal of neurosurgery 2005;102(6):1155–8.CrossRefPubMedGoogle Scholar
  42. 42.
    Simon CD, Sims PJ, Elston DM. Fatal cutaneous squamous cell carcinoma with extension through the maxillary sinus and orbit into the brain. Cutis; cutaneous medicine for the practitioner 1999;63(6):341–3.PubMedGoogle Scholar
  43. 43.
    Tai PT, Yu E, Winquist E, et al. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol 2000;18(12):2493–9.PubMedGoogle Scholar
  44. 44.
    Faye N, Lafitte F, Martin Duverneuil N, et al. Merkel cell tumor: report of two cases and review of the literature. Journal of neuroradiology 2005;32(2):138–41.CrossRefGoogle Scholar
  45. 45.
    Barkdull GC, Healy JF, Weisman RA. Intracranial spread of Merkel cell carcinoma through intact skull. The Annals of otology, rhinology, and laryngology 2004;113(9):683–7.PubMedGoogle Scholar
  46. 46.
    Turgut M. Brain metastasis of Merkel cell carcinoma. Neurosurgical review 2002;25(1–2):113–4.CrossRefPubMedGoogle Scholar
  47. 47.
    Ikawa F, Kiya K, Uozumi T, et al. Brain metastasis of Merkel cell carcinoma. Case report and review of the literature. Neurosurgical review 1999;22(1):54–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Gaurav D. Shah
    • 1
  • Lauren E. Abrey
    • 1
  1. 1.Department of NeurologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations